NEW YORK (GenomeWeb) – LabCorp subsidiary Esoterix Genetic Laboratories is suing Qiagen in a US district court alleging that Qiagen breached a licensing agreement between the companies regarding EGFR genetic testing by offering it for commercial research and diagnostic purposes ahead of US Food a
NEW YORK (GenomeWeb) – Researchers from Genzyme this month reported new proof-of-concept data showing that an expressed RNAi approach could be used to both prevent and treat the manifestations of Huntington's disease (HD) in an animal model of the condition.
Alnylam Pharmaceuticals announced this week that its partner Genzyme has exercised an option to buy 344,448 unregistered shares of Alnylam stock for $23 million as part of the companies broad genetic diseases alliance disclosed earlier this year.
On the heels of its acquisition of Merck's RNAi drug assets, Alnylam Pharmaceuticals this week announced that it has signed a deal giving partner Genzyme the rights to its existing and future genetic medicines programs in all territories outside of North America and Western Europ
Alnylam Pharmaceuticals last month announced that it has received a $7 million milestone payment from Genzyme based upon its positive data from a phase II trial of the TTR-mediated amyloidosis treatment patisiran, formerly known as ALN-TTR02.